TargetBeta
NR1H4
nuclear receptor subfamily 1 group H member 4 · also FXR, RIP14, HRR1, HRR-1 · Nuclear receptor subfamily 1 group H
2 programs in company-led studies act on NR1H4, from 2 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| cilofexorrule | Gilead Sciences | phase 3 | 131 running | – | ChEMBL |
| LY4395089 | Eli Lilly | phase 2 | 32 running | – | the company's pipeline |
Conditions their studies are in
- Cholangitis, Sclerosing, 1 program
- Colitis, Ulcerative, 1 program
- Crohn Disease, 1 program
- Liver Cirrhosis, Biliary, 1 program
- Non-alcoholic Fatty Liver Disease, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jun 2027LY4395089 · Eli Lilly · phase 2 · NCT07483099
- Dec 2028cilofexor · Gilead Sciences · phase 3 · NCT07841977
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.